Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis

Leukemia Research Reports

Volumn 4, Issue 1, 2015, Pages 36-38

  Sharma, Ruby ^a   Keyzner, Alla ^a   Liu, Johnson ^a   Bradley, Thomas ^a   Allen, Steven L ^a  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

Breakthrough PNH hemolysis complicating pregnancy; Escalated eculizumab dosing

Indexed keywords

CYCLOSPORIN; ECULIZUMAB; STEROID; THYMOCYTE ANTIBODY;

ADULT; ANEMIA; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CESAREAN SECTION; CHINESE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG RESPONSE; DYSERYTHROPOIESIS; ERYTHROCYTE TRANSFUSION; FEMALE; FLOW CYTOMETRY; GESTATION PERIOD; HEMOLYSIS; HUMAN; MYELODYSPLASTIC SYNDROME; PANCYTOPENIA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHARMACODYNAMICS; PREGNANCY OUTCOME; PRIORITY JOURNAL;

EID: 84937854926     PISSN: 22130489     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lrr.2015.05.001     Document Type: Article

References (14)

1. Fieni S, Bonfanti L, Gramellini D, Benassi L, Delsignore R. Clinical management of paroxysmal nocturnal hemoglobinuria in pregnancy: a case report and updated review. Obstet Gynecol Surv 2006, 61(9):593-601.
2. Thomas TC, Rollins SA, Rother RP, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 1996, 33:1389-1401.
3. Rinder CS, Rinder HM, Smith BR, Fitch JC, Smith MJ, Tracey JB, Matis LA, Squinto SP, Rollins SA. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 1995, 96:1564-1572.
4. Kelly R, Arnold L, Richards S, et al. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J Haematol 2010, 149(3):446-450.
5. Marasca R, Coluccio V, Santachiara R, et al. Pregnancy in PNH: another eculizumab baby. Br J Haematol 2010, 150(6):707-708.
6. Danilov AV, Smith H, Craigo S, Feeney DM, Relias V, Miller KB. Paroxysmal nocturnal hemoglobinuria (PNH) and pregnancy in the era of eculizumab. Leuk Res 2009, 33(6):e4-e5.
7. Roth A, Tokareva O, Hock C, Duhrsen U. Management of pregnancy in paroxysmal nocturnal hemoglobinuria (PNH) in the era of eculizumab: a case report and updated review. Onkologie 2011, 34(Suppl 6):67. Abstract 259.
8. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013, 368(23):2169-2181.
9. Shapira I, Andrade D, Allen SL, Salmon JE. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum 2012, 64(8):2719-2723.
10. Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011, 6:60.
11. Ardissino G, Ossola MW, Baffero GM, Rigotti A, Cugno M. Eculizumab for atypical hemolytic uremic syndrome in pregnancy. Obstet Gynecol 2013, 122:487-489.
12. Townsley DM, Young NS. Blood consult: paroxysmal nocturnal hemoglobinuria and its complications. Blood 2013, 122(16):2795-2798.
13. Bais J, Pel M, von dem Borne A, van der Lelie H. Pregnancy and paroxysmal nocturnal hemoglobinuria. Eur J Obstet Gynecol Reprod Biol 1994, 53:211-214.
14. Ray JG, Burows RF, Ginsberg JS, Burrows EA. Paroxysmal nocturnal hemoglobinuria and the risk of venous thrombosis: review and recommendations for management of the pregnant and nonpregnant patient. Haemostasis 2000, 30(3):103-117.